Skip to main content
Figure 2 | BMC Pharmacology

Figure 2

From: Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study

Figure 2

Increments of the pharmacodynamic markers neopterin and β 2 M. Data correspond to 15 healthy male subjects who received 180 μg of PEGASYS® (solid line) and formulation of 40-kDa PEG IFN alpha-2b (dashed line) at time 0. (A): Average neopterin concentration in serum, measured by EIA. (B): Average β2-microglobulin concentration in serum, measured by EIA. Standard deviations are not shown for the sake of simplicity of the illustration.

Back to article page